Analysis of treatment protocols using azithromycin eye drops for bacterial blepharitis: second report-bacteriological investigation.
Azithromycin
Blepharitis
Culture
Lid margin
Smear
Journal
Japanese journal of ophthalmology
ISSN: 1613-2246
Titre abrégé: Jpn J Ophthalmol
Pays: Japan
ID NLM: 0044652
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
26
01
2022
accepted:
15
08
2022
pubmed:
2
10
2022
medline:
15
12
2022
entrez:
1
10
2022
Statut:
ppublish
Résumé
To gain new insights into the etiology of blepharitis, we investigated the causative bacteria in patients with blepharitis and the effects of 1% azithromycin ophthalmic solution. A multicenter, prospective observational study. After the subjects were diagnosed as having blepharitis they were administered 1% azithromycin ophthalmic solution for up to 14 days. Bacterial cultures and smear microscopic examinations of the eyelid margin were conducted at the initial visit, after administering eye drops, and 1 month after the end of eye drop administration. The minimum inhibitory concentrations (MICs) of azithromycin were measured. At the initial visit, the bacterial morphology determined by smear microscopic examinations coincided with that of strains isolated by culture taken from 22 of 45 patients. All detected bacteria were gram-positive, and Corynebacterium spp., Cutibacterium acnes, Staphylococcus epidermidis, Streptococcus spp., and Enterococcus faecalis were isolated most commonly. Compared with the initial visit the number of isolated strains per eye decreased significantly at 7 days after the start of eye drop administration and 1 month after the end of eye drop administration. The azithromycin MICs were temporarily increased after the start of eye drops but then decreased. Our study suggests that in blepharitis pathogenicity is characterized by increased strain numbers and amounts of indigenous bacteria. Administering a 1% azithromycin ophthalmic solution suppresses the number of bacterial strains within 1 month after the end of eye drop administration without increasing drug resistance.
Identifiants
pubmed: 36181644
doi: 10.1007/s10384-022-00947-8
pii: 10.1007/s10384-022-00947-8
doi:
Substances chimiques
Azithromycin
83905-01-5
Ophthalmic Solutions
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
579-589Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. Japanese Ophthalmological Society.
Références
Amescua G, Akpek EK, Farid M, Garcia-Ferrer FJ, Lin A, Rhee MK, et al. Blepharitis preferred practice Pattern
doi: 10.1016/j.ophtha.2018.10.019
Eberhardt M, Rammohan G. Blepharitis. In: StatPearls [Internet]. StatPearls Publishing. 2021. https://www.ncbi.nlm.nih.gov/books/NBK459305 . Accessed 14 Sept 2021.
Nejima R, Shimizu K, Ono T, Noguchi Y, Yagi A, Iwasaki T, et al. Effect of the administration period of perioperative topical levofloxacin on normal conjunctival bacterial flora. J Cataract Refract Surg. 2017;43:42–8.
doi: 10.1016/j.jcrs.2016.10.024
Haque RM, Torkildsen GL, Brubaker K, Zink RC, Kowalski RP, Mah FS, et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. 2010;29:871–7.
doi: 10.1097/ICO.0b013e3181ca38a0
Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol. 1984;68:524–8.
doi: 10.1136/bjo.68.8.524
Huber-Spitzy V, Baumgartner I, Böhler-Sommeregger K, Grabner G. Blepharitis—a diagnostic and therapeutic challenge. A report on 407 consecutive cases. Graefes Arch Clin Exp Ophthalmol. 1991;229:224–7.
doi: 10.1007/BF00167872
Groden LR, Murphy B, Rodnite J, Genvert GI. Lid flora in blepharitis. Cornea. 1991;10:50–3.
doi: 10.1097/00003226-199110010-00010
Zhu M, Cheng C, Yi H, Lin L, Wu K. Quantitative analysis of the bacteria in blepharitis with demodex infestation. Front Microbiol. 2018;9:1719.
doi: 10.3389/fmicb.2018.01719
de Paula A, Oliva G, Barraquer RI, de la Paz MF. Prevalence and antibiotic susceptibility of bacteria isolated in patients affected with blepharitis in a tertiary eye centre in Spain. Eur J Ophthalmol. 2020;30:991–7.
doi: 10.1177/1120672119854985
Suzuki T, Mitsuishi Y, Sano Y, Yokoi N, Kinoshita S. Phlyctenular keratitis associated with Meibomitis in young patients. Am J Ophthalmol. 2005;140:77–82.
doi: 10.1016/j.ajo.2005.02.039
Suzuki T, Yokoi N, Kinoshita S. Clinical features of Meibomitis-relates keratoconjunctivitis in elderly patients. Atarashii Ganka (J Eye). 2018;35:389–94 (in Japanese).
Inoue Y, Ohashi Y, Hatano H, Shimomura Y, Sakamoto M, Okamoto Y, et al. Determination of causative agents in ocular infection of external adnexa and anterior segments-multicenter study of causative agents and drug sensitivity of ocular infection by the Japanese Association for Ocular Infection part I. Nippon Ganka Gakkai Zasshi. 2011;115:801–13 (In Japanese).
La Scolea Jr LJ, Dryja D. Quantitation of bacteria in cerebrospinal fluid and blood of children with meningitis and its diagnostic significance. J Clin Microbiol. 1984;19:187–90.
doi: 10.1128/jcm.19.2.187-190.1984
Nejima R, Inoue T, Kaji Y, Suzuki T, Hattori T, Hoshi S, et al. Analysis of treatment protocols using azithromycin eye drops for bacterial blepharitis—first report: study of clinical course. Atarashii Ganka (J Eye). 2022;39:999–1004 (in Japanese).
Azimycin ophthalmic solution 1%. Package insert. Senju Pharmaceutical Co., Ltd; 2020. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/380086_1317714Q1024_1_03 Accessed 11 Jan 2022 (in Japanese).
Clinical and Laboratory Standards Institute. M100. http://em100.edaptivedocs.net/dashboard.aspx Accessed 8 Nov 2021.
Everett SL, Kowalski RP, Karenchak LM, Landsittel D, Day R, Gordon YJ. An in vitro comparison of the susceptibilities of bacterial isolates from patients with conjunctivitis and blepharitis to newer and established topical antibiotics. Cornea. 1995;14:382–7.
doi: 10.1097/00003226-199507000-00006
Inoue Y, Usui M, Ohashi Y, Shiota H, Yamazaki T, Preoperative Disinfection Study Group. Preoperative disinfection of the conjunctival sac with antibiotics and iodine compounds: a prospective randomized multicenter study. Jpn J Ophthalmol. 2008;52:151–61.
doi: 10.1007/s10384-008-0517-y
Suzuki T, Tanaka H, Toriyama K, Okamoto S, Urabe K, Hashida M, et al. Prospective clinical evaluation of 1.5% levofloxacin ophthalmic solution in ophthalmic perioperative disinfection. J Ocul Pharmacol Ther. 2013;29:887–92.
doi: 10.1089/jop.2013.0146
Ono T, Nejima R, Iwasaki T, Mori Y, Noguchi Y, Yagi A, et al. Long-term effects of cataract surgery with topical levofloxacin on ocular bacterial flora. J Cataract Refract Surg. 2017;43:1129–34.
doi: 10.1016/j.jcrs.2017.06.037
Papa V, Blanco AR, Santocono M. Ocular flora and their antibiotic susceptibility in patients having cataract surgery in Italy. J Cataract Refract Surg. 2016;42:1312–7.
doi: 10.1016/j.jcrs.2016.07.022
Suzuki T, Todokoro D, Kobayakawa S, Sotozono C, Eguchi S, Miyata K, et al. Postcataract endophthalmitis caused by Enterococcus faecalis. Nippon Ganka Gakkai Zasshi. 2014;118:22–7 (in Japanese).
Kitamura Y, Yoshida K, Kusama M, Sugiyama Y. A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, C
doi: 10.2133/dmpk.DMPK-14-RG-013
Akpek EK, Vittitow J, Verhoeven RS, Brubaker K, Amar T, Powell KD, et al. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther. 2009;25:433–9.
doi: 10.1089/jop.2009.0026